Steinmetz Tali, Goldman Shira, Kagan Kim Ben Tikva, Bielopolski Dana, Buchrits Shira, Schechter Amir, Kushnir Shiri, Turjeman Adi, Agur Timna, Grossman Alon, Gvili Anat Gafter, Zvi Benaya Rozen
Department of Nephrology, Rabin Medical Center, Petach Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
J Clin Endocrinol Metab. 2025 Mar 22. doi: 10.1210/clinem/dgaf184.
To investigate the impact of Sodium-glucose cotransporter 2 (SGLT2) inhibitors on the incidence, complications, and therapeutic demands of anemia in patients with diabetes utilizing real-world data, compared to treatment with dipeptidyl peptidase 4 (DPP4) inhibitors.
In this retrospective cohort study, the dataset was sourced from the data repositories of Clalit Health Services. Since January 1, 2016 through December 31, 2021 we identified patients with type 2 diabetes who received treatment with SGLT2 inhibitors and compared them with a matched control group treated with DPP4 inhibitors using propensity score. The primary endpoint was prevalence of anemia.
A total of 22,896 patients included in this study, with 11,448 individuals administered SGLT2 inhibitors and an equal number treated with DPP4 inhibitors. We found a significant lower hazard of anemia among patients treated with SGLT2 inhibitors (HR=0.6, 95% CI 0.58-0.63) compared to those treated with DPP4 inhibitors. Moreover, the risk of hospitalizations attributed to anemia was significantly lower with SGLT2 inhibitors (HR 0.67, 95% CI 0.58-0.77). SGLT2 inhibitors were associated with a lower necessity for anemia treatment (HR 0.84, 95% CI 0.78-0.92, p < .001).
SGLT2 inhibitors demonstrated a lower prevalence of anemia and a lower risk of hospitalizations attributed to anemia when compared to treatment with DPP4 inhibitors in patients with diabetes.
利用真实世界数据，研究与二肽基肽酶4（DPP4）抑制剂治疗相比，钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂对糖尿病患者贫血发生率、并发症及治疗需求的影响。
在这项回顾性队列研究中，数据集来源于克拉利特医疗服务的数据仓库。自2016年1月1日至2021年12月31日，我们确定了接受SGLT2抑制剂治疗的2型糖尿病患者，并使用倾向评分将其与接受DPP4抑制剂治疗的匹配对照组进行比较。主要终点是贫血患病率。
本研究共纳入22896例患者，其中11448例接受SGLT2抑制剂治疗，另有11448例接受DPP4抑制剂治疗。我们发现，与接受DPP4抑制剂治疗的患者相比（HR=0.6，95%CI 0.58-0.63），接受SGLT2抑制剂治疗的患者贫血风险显著降低。此外，SGLT2抑制剂导致的因贫血住院风险也显著降低（HR 0.67，95%CI 0.58-0.77）。SGLT2抑制剂与较低的贫血治疗需求相关（HR 0.84，95%CI 0.78-0.92，p<0.001）。
与DPP4抑制剂治疗相比，SGLT2抑制剂在糖尿病患者中显示出较低的贫血患病率和因贫血住院的风险。
